Goodwin Procter

Boston-headquartered Goodwin distinguishes itself with a strategic focus on five key industries, namely life sciences, technology, private equity, real estate, and financial services, and capitalises on the convergence between them (“where capital meets innovation”). This strong sectoral focus is paired with a distinguished M&A practice that has secured the top spot globally by deal count for at least four consecutive years from 2020 to 2023. In 2023, the two UK offices (London and Cambridge) combined generated $174.4m in revenue, accounting for 7.8% of the firm’s global revenue. In terms of headcount, the London office grew by 68% from 140 lawyers including 43 partners in March 2021 to 236 lawyers including 64 partners in 2024. In 2020, the London office established its Complex Disputes & Litigation expertise, focusing on investment, post-transactional and shareholder disputes. The team now takes on one to two trainees for every seat rotation. Goodwin's UK offices in London and Cambridge exemplify the firm’s commitment to life sciences and technology growth companies, including Vicebio (pharma), Myricx (biotech), and Scalpel AI (healthtech), and their investors, such as TA Associates, Latour Capital, and Cambridge Innovation Capital. The UK forms a key part of Goodwin’s international venture capital and growth network, which spans 16 global innovation hubs and financial centers, such as Silicon Valley, San Francisco, New York, Munich, Frankfurt, Hong Kong and Singapore. Goodwin’s London team is also a market leader in real estate and private fund formation, with a top-ranking practice working closely with Luxembourg, Europe’s fund hub.The team recently advised Advent International on the successful completion of its fundraising for Advent International GPE IX, which reached its hard cap of $17.5 billion.